Phage Display and PEGylation of Therapeutic Proteins

Author(s): Yohei Mukai, Yasuo Yoshioka, Yasuo Tsutsumi

Journal Name: Combinatorial Chemistry & High Throughput Screening
Accelerated Technologies for Biotechnology, Bioassays, Medicinal Chemistry and Natural Products Research

Volume 8 , Issue 2 , 2005

Become EABM
Become Reviewer
Call for Editor


With the success of the human genome project, the focus of life science research has shifted to the functional and structural analyses of proteins, such as disease proteomics and structural genomics. These novel approaches to the analyses of proteins, including newly identified ones, are expected to help in the identification and development of protein therapies for various diseases. Thus, disease proteomic-based drug discovery has a very high profile. Nevertheless, the use of bioactive proteins in the clinical setting is not straightforward because, in vivo, these proteins have a low stability and a pleiotropic action. To promote disease proteomic-based drug discovery and development, we have attempted to establish a system for creating functional mutant proteins (muteins) with the desired properties, and also to develop a site-specific polymerconjugation system for further improving their therapeutic potency. These innovative protein-drug systems are discussed in this review.

Keywords: conjugation, pegylation, polyethylene glycol, polyvinylpyrrolidone, tumor necrosis factor-alpha, protein therapy, phage library, high throughput screening

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [145 - 152]
Pages: 8
DOI: 10.2174/1386207053258578
Price: $65

Article Metrics

PDF: 3